{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:44:28Z","timestamp":1794037468998,"version":"4.8.0"},"reference-count":175,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.cyto.2022.155897","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T13:00:12Z","timestamp":1654520412000},"page":"155897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"special_numbering":"C","title":["Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions"],"prefix":"10.1016","volume":"156","author":[{"given":"Kacey L.","family":"Sachen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie N.","family":"Arnold Greving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Towne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0005","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.4049\/jimmunol.167.3.1440","article-title":"Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2","volume":"167","author":"Debets","year":"2001","journal-title":"J Immunol"},{"issue":"14","key":"10.1016\/j.cyto.2022.155897_b0010","doi-asserted-by":"crossref","first-page":"13677","DOI":"10.1074\/jbc.M400117200","article-title":"Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs","volume":"279","author":"Towne","year":"2004","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.cyto.2022.155897_b0015","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4049\/jimmunol.1003162","article-title":"IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression","volume":"186","author":"Johnston","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.cyto.2022.155897_b0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.1016\/j.cyto.2022.155897_b0025","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0030","doi-asserted-by":"crossref","first-page":"15631","DOI":"10.1038\/s41598-017-15892-7","article-title":"The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function","volume":"7","author":"Pfaff","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.cyto.2022.155897_b0035","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3749","article-title":"IkB\u03b6 is a Key Regulator of Tumour Necrosis Factor-a and Interleukin-17A-mediated Induction of Interleukin-36g in Human Keratinocytes","volume":"101","author":"Ovesen","year":"2021","journal-title":"Acta Dermato-Venereologica"},{"issue":"411","key":"10.1016\/j.cyto.2022.155897_b0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2514","article-title":"An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target","volume":"9","author":"Mahil","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cyto.2022.155897_b0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fimmu.2018.00080","article-title":"RNA-Seq Analysis of IL-1B and IL-36 Responses in Epidermal Keratinocytes Identifies a Shared MyD88-Dependent Gene Signature","volume":"9","author":"Swindell","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.cyto.2022.155897_b0050","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jid.2021.01.019","article-title":"IL-36 and IL-17A Cooperatively Induce a Psoriasis-Like Gene Expression Response in Human Keratinocytes","volume":"141","author":"Miura","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"22","key":"10.1016\/j.cyto.2022.155897_b0055","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1182\/blood-2011-05-356873","article-title":"IL-36R ligands are potent regulators of dendritic and T cells","volume":"118","author":"Vigne","year":"2011","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.cyto.2022.155897_b0060","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/blood-2012-06-439026","article-title":"IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells","volume":"120","author":"Vigne","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cyto.2022.155897_b0065","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1172\/JCI63451","article-title":"Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk","volume":"122","author":"Tortola","year":"2012","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.cyto.2022.155897_b0070","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdermsci.2015.08.002","article-title":"Expression of IL-36 family cytokines and IL-37 but not IL-38 is altered in psoriatic skin","volume":"80","author":"Keermann","year":"2015","journal-title":"J Dermatol Sci"},{"issue":"11","key":"10.1016\/j.cyto.2022.155897_b0075","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/s41419-018-1143-3","article-title":"IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment","volume":"9","author":"Mercurio","year":"2018","journal-title":"Cell Death Dis"},{"issue":"49","key":"10.1016\/j.cyto.2022.155897_b0080","doi-asserted-by":"crossref","first-page":"42594","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity","volume":"286","author":"Towne","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cyto.2022.155897_b0085","doi-asserted-by":"crossref","first-page":"24880","DOI":"10.1038\/srep24880","article-title":"Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist","volume":"6","author":"Macleod","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.cyto.2022.155897_b0090","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.cyto.2022.155897_b0095","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1111\/febs.14075","article-title":"Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines","volume":"284","author":"Clancy","year":"2017","journal-title":"FEBS J"},{"key":"10.1016\/j.cyto.2022.155897_b0100","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3389\/fimmu.2019.00746","article-title":"Neutrophil Extracellular Traps Promote Inflammatory Responses in Psoriasis via Activating Epidermal TLR4\/IL-36R Crosstalk","volume":"10","author":"Shao","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0105","doi-asserted-by":"crossref","first-page":"20149","DOI":"10.1038\/s41598-020-76864-y","article-title":"Neutrophil extracellular traps are induced in a psoriasis model of interleukin-36 receptor antagonist-deficient mice","volume":"10","author":"Watanabe","year":"2020","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.cyto.2022.155897_b0110","doi-asserted-by":"crossref","first-page":"E2748","DOI":"10.1073\/pnas.1620954114","article-title":"Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36gamma","volume":"114","author":"Ainscough","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.cyto.2022.155897_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108515","article-title":"The Proinflammatory Cytokine IL-36gamma Is a Global Discriminator of Harmless Microbes and Invasive Pathogens within Epithelial Tissues","volume":"33","author":"Macleod","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.cyto.2022.155897_b0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/5584_2020_488","article-title":"Interleukin-36: Structure, Signaling and Function","volume":"21","author":"Zhou","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1016\/j.cyto.2022.155897_b0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1074\/jbc.M117.805739","article-title":"Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation","volume":"293","author":"Zhou","year":"2018","journal-title":"J Biol Chem"},{"issue":"32","key":"10.1016\/j.cyto.2022.155897_b0130","doi-asserted-by":"crossref","first-page":"16597","DOI":"10.1074\/jbc.M116.723064","article-title":"Structural and Functional Attributes of the Interleukin-36 Receptor","volume":"291","author":"Yi","year":"2016","journal-title":"J Biol Chem"},{"issue":"39","key":"10.1016\/j.cyto.2022.155897_b0135","doi-asserted-by":"crossref","first-page":"23997","DOI":"10.1074\/jbc.M115.653378","article-title":"Signal Transduction and Intracellular Trafficking by the Interleukin 36 Receptor","volume":"290","author":"Saha","year":"2015","journal-title":"J Biol Chem"},{"issue":"37","key":"10.1016\/j.cyto.2022.155897_b0140","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.1021\/bi0341197","article-title":"High-resolution structure of murine interleukin 1 homologue IL-1F5 reveals unique loop conformations for receptor binding specificity","volume":"42","author":"Dunn","year":"2003","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.cyto.2022.155897_b0145","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4049\/jimmunol.1400538","article-title":"Molecular determinants of agonist and antagonist signaling through the IL-36 receptor","volume":"193","author":"Gunther","year":"2014","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.cyto.2022.155897_b0150","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1073\/pnas.1121534109","article-title":"IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist","volume":"109","author":"van de Veerdonk","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194667","article-title":"The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expression","volume":"13","author":"Palomo","year":"2018","journal-title":"PLoS One"},{"issue":"26","key":"10.1016\/j.cyto.2022.155897_b0160","doi-asserted-by":"crossref","first-page":"25233","DOI":"10.1074\/jbc.M501363200","article-title":"SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms","volume":"280","author":"Qin","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cyto.2022.155897_b0165","article-title":"SIGIRR Negatively Regulates IL-36-Driven Psoriasiform Inflammation and Neutrophil Infiltration in the Skin","author":"Giannoudaki","year":"2021","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.cyto.2022.155897_b0170","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900586","article-title":"Keratinocyte interleukin-36 receptor expression orchestrates psoriasiform inflammation in mice","volume":"3","author":"Hernandez-Santana","year":"2020","journal-title":"Life Sci Alliance"},{"issue":"12","key":"10.1016\/j.cyto.2022.155897_b0175","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.4049\/jimmunol.1301481","article-title":"IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin","volume":"192","author":"Foster","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.cyto.2022.155897_b0180","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cyto.2016.05.012","article-title":"Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines","volume":"84","author":"Dietrich","year":"2016","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.cyto.2022.155897_b0185","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.immuni.2011.09.010","article-title":"Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E","volume":"35","author":"Chang","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2022.155897_b0190","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fimmu.2018.00200","article-title":"IL-36gamma Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis","volume":"9","author":"Bridgewood","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.cyto.2022.155897_b0195","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/exd.13228","article-title":"IL-36gamma has proinflammatory effects on human endothelial cells","volume":"26","author":"Bridgewood","year":"2017","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.cyto.2022.155897_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222969","article-title":"Interleukin (IL)-17\/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses","volume":"15","author":"Mercurio","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cyto.2022.155897_b0205","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1681\/ASN.2016080840","article-title":"IL-36 Signaling Facilitates Activation of the NLRP3 Inflammasome and IL-23\/IL-17 Axis in Renal Inflammation and Fibrosis","volume":"28","author":"Chi","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0210","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/eji.201142035","article-title":"Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9","volume":"42","author":"Mutamba","year":"2012","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.cyto.2022.155897_b0215","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jid.2019.08.444","article-title":"IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis","volume":"140","author":"Catapano","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0220","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jid.2017.12.024","article-title":"Unopposed IL-36 Activity Promotes Clonal CD4(+) T-Cell Responses with IL-17A Production in Generalized Pustular Psoriasis","volume":"138","author":"Arakawa","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0225","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000688","article-title":"IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis","volume":"3","author":"Goldstein","year":"2020","journal-title":"Life Sci Alliance"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0230","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jid.2018.12.003","article-title":"IL-36 Signaling Is Essential for Psoriatic Inflammation through the Augmentation of Innate Immune Responses","volume":"139","author":"Ohko","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.cyto.2022.155897_b0235","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1084\/jem.20070157","article-title":"Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation","volume":"204","author":"Blumberg","year":"2007","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.cyto.2022.155897_b0240","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.4049\/jimmunol.1000313","article-title":"IL-1RL2 and its ligands contribute to the cytokine network in psoriasis","volume":"185","author":"Blumberg","year":"2010","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.cyto.2022.155897_b0245","article-title":"Establishment of an Intradermal Ear Injection Model of IL-17A and IL-36gamma as a Tool to Investigate the Psoriatic Cytokine Network","volume":"11","author":"Kluwig","year":"2021","journal-title":"Life (Basel)"},{"issue":"7","key":"10.1016\/j.cyto.2022.155897_b0250","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/19420862.2017.1353853","article-title":"Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies","volume":"9","author":"Ganesan","year":"2017","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.cyto.2022.155897_b0255","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/exd.13841","article-title":"IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis","volume":"28","author":"Su","year":"2019","journal-title":"Exp Dermatol"},{"issue":"40","key":"10.1016\/j.cyto.2022.155897_b0260","doi-asserted-by":"crossref","first-page":"10088","DOI":"10.1073\/pnas.1801377115","article-title":"IkappaBzeta is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytes","volume":"115","author":"Muller","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10.1016\/j.cyto.2022.155897_b0265","article-title":"Keratinocyte-derived IkappaBzeta drives psoriasis and associated systemic inflammation. JCI","volume":"4","author":"Lorscheid","year":"2019","journal-title":"Insight"},{"issue":"9","key":"10.1016\/j.cyto.2022.155897_b0270","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0275","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4049\/jimmunol.1102224","article-title":"IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice","volume":"188","author":"Van Belle","year":"2012","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0280","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.cyto.2022.155897_b0285","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1038\/jid.2015.289","article-title":"Unprocessed Interleukin-36alpha Regulates Psoriasis-Like Skin Inflammation in Cooperation With Interleukin-1","volume":"135","author":"Milora","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"54","key":"10.1016\/j.cyto.2022.155897_b0290","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax1686","article-title":"Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine","volume":"5","author":"Hovhannisyan","year":"2020","journal-title":"Sci Immunol"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0295","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/sj.jid.5700807","article-title":"Mouse models of psoriasis","volume":"127","author":"Gudjonsson","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.cyto.2022.155897_b0300","series-title":"Global Report on psoriasis","author":"Who","year":"2016"},{"key":"10.1016\/j.cyto.2022.155897_b0305","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1101\/cshperspect.a015354","article-title":"Psoriasis","volume":"4","author":"Di Meglio","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10281","key":"10.1016\/j.cyto.2022.155897_b0310","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cyto.2022.155897_b0315","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/med.21291","article-title":"Keratin 17: a critical player in the pathogenesis of psoriasis","volume":"34","author":"Jin","year":"2014","journal-title":"Med Res Rev"},{"issue":"11","key":"10.1016\/j.cyto.2022.155897_b0320","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/exd.13378","article-title":"Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes","volume":"26","author":"Fuentes-Duculan","year":"2017","journal-title":"Exp Dermatol"},{"issue":"244","key":"10.1016\/j.cyto.2022.155897_b0325","doi-asserted-by":"crossref","first-page":"p. 244ra90","DOI":"10.1126\/scitranslmed.3008946","article-title":"Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema","volume":"6","author":"Quaranta","year":"2014","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.cyto.2022.155897_b0330","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/jid.2014.532","article-title":"IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions","volume":"135","author":"D'Erme","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.cyto.2022.155897_b0335","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.jid.2016.03.020","article-title":"IL-36gamma Is Involved in Psoriasis and Allergic Contact Dermatitis","volume":"136","author":"Balato","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0340","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small Molecule IL-36gamma Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis","volume":"9","author":"Todorovic","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cyto.2022.155897_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2021.03.019","article-title":"IRAK2 Has a Critical Role in Promoting Feed-Forward Amplification of Epidermal Inflammatory Responses","author":"Shao","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.cyto.2022.155897_b0350","article-title":"IL-36alpha and IL-36gamma expressions in the differential diagnosis of palmoplantar psoriasis and palmoplantar eczema: a retrospective histopathologic and immunohistochemical study","author":"Erdem","year":"2021","journal-title":"J Cutan Pathol"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0355","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jaci.2018.04.031","article-title":"Detection of IL-36gamma through noninvasive tape stripping reliably discriminates psoriasis from atopic eczema","volume":"142","author":"Berekmeri","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0360","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.celrep.2019.03.082","article-title":"IL-38 Ameliorates Skin Inflammation and Limits IL-17 Production from gammadelta T Cells","volume":"27","author":"Han","year":"2019","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.cyto.2022.155897_b0365","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1111\/ijd.12562","article-title":"Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis","volume":"53","author":"Taheri Sarvtin","year":"2014","journal-title":"Int J Dermatol"},{"issue":"11","key":"10.1016\/j.cyto.2022.155897_b0370","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1111\/jdv.14994","article-title":"Candida induces the expression of IL-36gamma in human keratinocytes: implications for a pathogen-driven exacerbation of psoriasis?","volume":"32","author":"Braegelmann","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0375","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.1992.01680110049004","article-title":"The role of streptococcal infection in the initiation of guttate psoriasis","volume":"128","author":"Telfer","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cyto.2022.155897_b0380","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-206899","article-title":"The role of tonsillectomy in psoriasis treatment","author":"Simoes","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0385","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"beta-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.cyto.2022.155897_b0390","first-page":"1","article-title":"Downregulation of interleukin 36gamma and its cleaver cathepsin G following treatment with narrow-band ultraviolet B phototherapy in psoriasis vulgaris","author":"El-Kalioby","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.cyto.2022.155897_b0395","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.56991","article-title":"Dithranol targets keratinocytes, their crosstalk with neutrophils and inhibits the IL-36 inflammatory loop in psoriasis","volume":"9","author":"Benezeder","year":"2020","journal-title":"Elife"},{"issue":"9","key":"10.1016\/j.cyto.2022.155897_b0400","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","article-title":"An update on generalized pustular psoriasis","volume":"15","author":"Gooderham","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"10.1016\/j.cyto.2022.155897_b0405","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/archderm.1991.01680080075005","article-title":"Generalized pustular psoriasis. a review of 63 cases","volume":"127","author":"Zelickson","year":"1991","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0410","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/ijd.12070","article-title":"Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor","volume":"53","author":"Choon","year":"2014","journal-title":"Malaysia. Int J Dermatol"},{"key":"10.1016\/j.cyto.2022.155897_b0415","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-021-01076-6","article-title":"SARS-CoV-2 infection inducing severe flare up of Deficiency of Interleukin Thirty-six (IL-36) Receptor Antagonist (DITRA) resulting from a mutation invalidating the activating cleavage site of the IL-36 receptor antagonist","author":"Bozonnat","year":"2021","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0420","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.cyto.2022.155897_b0425","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/1203475418758986","article-title":"Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease","volume":"22","author":"Almutairi","year":"2018","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0430","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/09546634.2010.534430","article-title":"Flare of pustular psoriasis after initiating ustekinumab therapy","volume":"23","author":"Wenk","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.cyto.2022.155897_b0435","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/11586900-000000000-00000","article-title":"Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients","volume":"12","author":"Borges-Costa","year":"2011","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0440","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jaci.2017.05.019","article-title":"Autoinflammatory keratinization diseases","volume":"140","author":"Akiyama","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.cyto.2022.155897_b0445","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jdermsci.2018.01.012","article-title":"Autoinflammatory keratinization diseases: an emerging concept encompassing various inflammatory keratinization disorders of the skin","volume":"90","author":"Akiyama","year":"2018","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.cyto.2022.155897_b0450","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fimmu.2020.00280","article-title":"Autoinflammatory Keratinization Diseases (AiKDs): Expansion of Disorders to Be Included","volume":"11","author":"Akiyama","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0455","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.cyto.2022.155897_b0460","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0465","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/humu.22203","article-title":"Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis","volume":"34","author":"Farooq","year":"2013","journal-title":"Hum Mutat"},{"issue":"11","key":"10.1016\/j.cyto.2022.155897_b0470","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1038\/jid.2013.214","article-title":"Mutations in IL36RN in patients with generalized pustular psoriasis","volume":"133","author":"Korber","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0475","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jdermsci.2014.02.006","article-title":"The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants","volume":"74","author":"Sugiura","year":"2014","journal-title":"J Dermatol Sci"},{"issue":"10","key":"10.1016\/j.cyto.2022.155897_b0480","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/exd.13387","article-title":"Mutation in IL36RN impairs the processing and regulatory function of the interleukin-36-receptor antagonist and is associated with DITRA syndrome","volume":"28","author":"Bal","year":"2019","journal-title":"Exp Dermatol"},{"issue":"11","key":"10.1016\/j.cyto.2022.155897_b0485","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/jid.2013.230","article-title":"The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist","volume":"133","author":"Sugiura","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0490","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.cyto.2022.155897_b0495","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2016.10.021","article-title":"Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders","volume":"139","author":"Liang","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.cyto.2022.155897_b0500","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jaci.2017.12.972","article-title":"The activation and function of IL-36gamma in neutrophilic inflammation in chronic rhinosinusitis","volume":"141","author":"Wang","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.cyto.2022.155897_b0505","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cyto.2022.155897_b0510","unstructured":"ClinicalTrials.gov. A Study to Test BI 655130 in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis. September, 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03782792."},{"key":"10.1016\/j.cyto.2022.155897_b0515","unstructured":"ClinicalTrials.gov. A 5-year Study to Test BI 655130 in Patients With Generalized Pustular Psoriasis Who Took Part in Previous Studies With BI 655130. September, 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03886246."},{"key":"10.1016\/j.cyto.2022.155897_b0520","unstructured":"ClinicalTrials.gov. A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis. September, 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04399837."},{"key":"10.1016\/j.cyto.2022.155897_b0525","unstructured":"ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis (GPP). September, 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619902."},{"key":"10.1016\/j.cyto.2022.155897_b0530","unstructured":"ANAPTYSBIO, ANAPTYSBIO PRESENTS UPDATED DATA FROM IMSIDOLIMAB PHASE 2 GALLOP TRIAL IN GENERALIZED PUSTULAR PSORIASIS. 2021."},{"key":"10.1016\/j.cyto.2022.155897_b0535","doi-asserted-by":"crossref","first-page":"62","DOI":"10.12703\/r\/10-62","article-title":"Recent advances in palmoplantar pustulosis","volume":"10","author":"Brunasso","year":"2021","journal-title":"Fac Rev"},{"issue":"4","key":"10.1016\/j.cyto.2022.155897_b0540","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2340\/0001555551284288","article-title":"Pustulosis palmaris et plantaris. Prevalence, clinical observations and prognosis","volume":"51","author":"Hellgren","year":"1971","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.cyto.2022.155897_b0545","first-page":"1","article-title":"Prevalence of Skin Diseases in a Population; a Census Study from the Faroe Islands","volume":"11","author":"Lomholt","year":"1964","journal-title":"Dan Med Bull"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0550","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006450","article-title":"Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database","volume":"5","author":"Kubota","year":"2015","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.cyto.2022.155897_b0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155215","article-title":"Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris","volume":"11","author":"Bissonnette","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.cyto.2022.155897_b0560","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1038\/jid.2010.87","article-title":"Acrosyringium is the main site of the vesicle\/pustule formation in palmoplantar pustulosis","volume":"130","author":"Murakami","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0565","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2133.2010.09819.x","article-title":"Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis","volume":"163","author":"Hagforsen","year":"2010","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.cyto.2022.155897_b0570","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1600-0625.2011.01325.x","article-title":"Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum","volume":"20","author":"Murakami","year":"2011","journal-title":"Exp Dermatol"},{"issue":"10","key":"10.1016\/j.cyto.2022.155897_b0575","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/jdv.12272","article-title":"Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial","volume":"28","author":"Bissonnette","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0580","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamadermatol.2017.5937","article-title":"Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: a Randomized Clinical Trial","volume":"154","author":"Terui","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.cyto.2022.155897_b0585","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/jamadermatol.2019.1394","article-title":"Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: a Phase 3 Randomized Clinical Trial","volume":"155","author":"Terui","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.cyto.2022.155897_b0590","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/jid.2015.186","article-title":"Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but Not with Loss-of-Function Mutations in IL36RN in European Patients","volume":"135","author":"Mossner","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0595","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/1346-8138.13551","article-title":"Mutation analysis of IL36RN gene in Japanese patients with palmoplantar pustulosis","volume":"44","author":"Takahashi","year":"2017","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0600","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and genetic differences between pustular psoriasis subtypes","volume":"143","author":"Twelves","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0605","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ced.13689","article-title":"Interleukin (IL)-8 and IL-36gamma but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis","volume":"44","author":"Xiaoling","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdermsci.2016.08.300","article-title":"IL-1 and IL-36 are the dominant cytokines in palmar plantar pustulosis","volume":"84","author":"Johnston","year":"2016","journal-title":"Journal of Dermatological Science"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0615","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jid.2020.09.028","article-title":"Cigarette Smoke Underlies the Pathogenesis of Palmoplantar Pustulosis via an IL-17A-Induced Production of IL-36gamma in Tonsillar Epithelial Cells","volume":"141","author":"Kobayashi","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0620","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/1346-8138.13751","article-title":"Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal","volume":"44","author":"Kouno","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.cyto.2022.155897_b0625","first-page":"193","article-title":"Animal model of focal tonsillar infection: human tonsillar lymphocytes induce skin lesion in SCID mice","volume":"523","author":"Hayashi","year":"1996","journal-title":"Acta Otolaryngol Suppl"},{"issue":"7","key":"10.1016\/j.cyto.2022.155897_b0630","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3950\/jibiinkoka.103.796","article-title":"A study of the pathogenesis of tonsillar focal infection\u2013transplantation of human tonsillar lymphocytes and human skin into SCID mice","volume":"103","author":"Yamamoto","year":"2000","journal-title":"Nihon Jibiinkoka Gakkai Kaiho"},{"issue":"7","key":"10.1016\/j.cyto.2022.155897_b0635","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1348-0421.2001.tb02651.x","article-title":"Engraftment of tonsillar mononuclear cells in human skin\/SCID mouse chimera\u2013validation of a novel xenogeneic transplantation model for autoimmune diseases","volume":"45","author":"Yamanaka","year":"2001","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.cyto.2022.155897_b0640","unstructured":"ANAPTYSBIO, ANAPTYSBIO REPORTS IMSIDOLIMAB POPLAR PHASE 2 CLINICAL TRIAL IN MODERATE-TO-SEVERE PALMOPLANTAR PUSTULOSIS (PPP) DID NOT MEET PRIMARY ENDPOINT. 2021."},{"issue":"2","key":"10.1016\/j.cyto.2022.155897_b0645","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","article-title":"Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: results of a Phase IIa, Multicenter, Double-Blind, Randomized","volume":"11","author":"Mrowietz","year":"2021","journal-title":"Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.cyto.2022.155897_b0650","unstructured":"ClinicalTrials.gov. A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis. September, 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04015518."},{"key":"10.1016\/j.cyto.2022.155897_b0655","unstructured":"ClinicalTrials.gov. A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab. September, 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04493424."},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0660","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa","volume":"183","author":"Wolk","year":"2020","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.cyto.2022.155897_b0665","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","article-title":"Prevalence of Hidradenitis Suppurativa: a Systematic Review and Meta-regression Analysis","volume":"157","author":"Jfri","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.cyto.2022.155897_b0670","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/jamadermatol.2018.0141","article-title":"Association of Hidradenitis Suppurativa With T Helper 1\/T Helper 17 Phenotypes: a Semantic Map Analysis","volume":"154","author":"Thomi","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0675","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"19","key":"10.1016\/j.cyto.2022.155897_b0680","article-title":"Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis. JCI","volume":"5","author":"Gudjonsson","year":"2020","journal-title":"Insight"},{"issue":"12","key":"10.1016\/j.cyto.2022.155897_b0685","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/jdv.14389","article-title":"Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa","volume":"31","author":"Thomi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.cyto.2022.155897_b0690","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00403-017-1769-5","article-title":"IL-36 cytokines are increased in acne and hidradenitis suppurativa","volume":"309","author":"Di Caprio","year":"2017","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0695","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.16019","article-title":"Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop","volume":"178","author":"Hessam","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0700","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction","volume":"139","author":"Witte-Handel","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0705","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00403-019-02012-w","article-title":"Serum IL-36alpha, IL-36beta, and IL-36gamma levels in patients with hidradenitis suppurativa: association with disease characteristics, smoking, obesity, and metabolic syndrome","volume":"312","author":"Hayran","year":"2020","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0710","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjd.19795","article-title":"Activity and components of the granulocyte colony-stimulating factor pathway in hidradenitis suppurativa","volume":"185","author":"Wolk","year":"2021","journal-title":"Br J Dermatol"},{"issue":"10023","key":"10.1016\/j.cyto.2022.155897_b0715","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0720","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.anai.2019.10.008","article-title":"The role of filaggrin in atopic dermatitis and allergic disease","volume":"124","author":"Drislane","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0725","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.cyto.2022.155897_b0730","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","article-title":"RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications","volume":"135","author":"Suarez-Farinas","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.cyto.2022.155897_b0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2021.04.023","article-title":"Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients","author":"Lang","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0740","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2018.08.024","article-title":"Atopic dermatitis in African American patients is TH2\/TH22-skewed with TH1\/TH17 attenuation","volume":"122","author":"Sanyal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdermsci.2010.02.008","article-title":"Extrinsic and intrinsic types of atopic dermatitis","volume":"58","author":"Tokura","year":"2010","journal-title":"J Dermatol Sci"},{"issue":"2","key":"10.1016\/j.cyto.2022.155897_b0750","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis","volume":"132","author":"Suarez-Farinas","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0755","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/exd.12967","article-title":"Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis","volume":"25","author":"Martel","year":"2016","journal-title":"Exp Dermatol"},{"issue":"5","key":"10.1016\/j.cyto.2022.155897_b0760","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","article-title":"Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses","volume":"145","author":"Tsoi","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.cyto.2022.155897_b0765","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.7150\/ijms.20809","article-title":"IL-36gamma inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis","volume":"14","author":"Wang","year":"2017","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.cyto.2022.155897_b0770","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4939-6786-5_8","article-title":"A Mouse Model for Atopic Dermatitis Using Topical Application of Vitamin D3 or of Its Analog MC903","volume":"1559","author":"Moosbrugger-Martinz","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.1016\/j.cyto.2022.155897_b0775","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.90","article-title":"Experimental atopic dermatitis depends on IL-33R signaling via MyD88 in dendritic cells","volume":"8","author":"Li","year":"2017","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.cyto.2022.155897_b0780","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.chom.2017.10.006","article-title":"Staphylococcus aureus Epicutaneous Exposure Drives Skin Inflammation via IL-36-Mediated T Cell Responses","volume":"22","author":"Liu","year":"2017","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.cyto.2022.155897_b0785","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.chom.2017.10.008","article-title":"Staphylococcus aureus Virulent PSMalpha Peptides Induce Keratinocyte Alarmin Release to Orchestrate IL-17-Dependent Skin Inflammation","volume":"22","author":"Nakagawa","year":"2017","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.cyto.2022.155897_b0790","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143334","article-title":"Epicutaneous Staphylococcus aureus induces IL-36 to enhance IgE production and ensuing allergic disease","volume":"131","author":"Patrick","year":"2021","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0795","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/dth.12325","article-title":"Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab","volume":"29","author":"Pan","year":"2016","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0800","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10875-019-00622-7","article-title":"Interleukin-36 Receptor Antagonist Deficiency (DITRA) with a Novel IL36RN Homozygous Mutation c.200G > T (P.Cys67Phe) in a Young Colombian Woman","volume":"39","author":"Zea-Vera","year":"2019","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0805","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.anai.2020.10.003","article-title":"A review of contact dermatitis","volume":"126","author":"Brar","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.cyto.2022.155897_b0810","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jaci.2014.03.009","article-title":"Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response","volume":"134","author":"Dhingra","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0815","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2017.02.001","article-title":"Association between atopic dermatitis and contact sensitization: a systematic review and meta-analysis","volume":"77","author":"Hamann","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cyto.2022.155897_b0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109687","article-title":"New aspect of allergic contact dermatitis, an inflammatory skin disorder mediated by mast cells: Can IL-38 help?","volume":"139","author":"Lauritano","year":"2020","journal-title":"Med Hypotheses"},{"issue":"12","key":"10.1016\/j.cyto.2022.155897_b0825","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/exd.12272","article-title":"The balance between pro- and anti-inflammatory cytokines is crucial in human allergic contact dermatitis pathogenesis: the role of IL-1 family members","volume":"22","author":"Mattii","year":"2013","journal-title":"Exp Dermatol"},{"issue":"14","key":"10.1016\/j.cyto.2022.155897_b0830","doi-asserted-by":"crossref","first-page":"10308","DOI":"10.1074\/jbc.275.14.10308","article-title":"Identification and initial characterization of four novel members of the interleukin-1 family","volume":"275","author":"Kumar","year":"2000","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.cyto.2022.155897_b0835","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bbrc.2018.10.104","article-title":"IL-36alpha is involved in hapten-specific T-cell induction, but not local inflammation, during contact hypersensitivity","volume":"506","author":"Numata","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.cyto.2022.155897_b0840","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jid.2017.12.033","article-title":"Regnase-1, an Immunomodulator, Limits the IL-36\/IL-36R Autostimulatory Loop in Keratinocytes to Suppress Skin Inflammation","volume":"138","author":"Takaishi","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.cyto.2022.155897_b0845","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1111\/all.14260","article-title":"Interleukin-36 (IL-36) system in the 1-fluoro-2,4-dinitrobenzene (DNFB) mouse model of allergic contact dermatitis","volume":"75","author":"Zaladonis","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.cyto.2022.155897_b0850","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41598-020-57550-5","article-title":"TAK-242 ameliorates contact dermatitis exacerbated by IL-36 receptor antagonist deficiency","volume":"10","author":"Fukushima","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cyto.2022.155897_b0855","unstructured":"ClinicalTrials.gov. A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa. October 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04762277."},{"key":"10.1016\/j.cyto.2022.155897_b0860","unstructured":"ClinicalTrials.gov. A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial. October 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04876391."},{"key":"10.1016\/j.cyto.2022.155897_b0865","unstructured":"ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa. October 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04856930."},{"key":"10.1016\/j.cyto.2022.155897_b0870","unstructured":"ClinicalTrials.gov. A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated. October 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03822832."},{"key":"10.1016\/j.cyto.2022.155897_b0875","unstructured":"ClinicalTrials.gov. A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032. October 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04086121."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466622001065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466622001065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:46:03Z","timestamp":1760910363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466622001065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":175,"alternative-id":["S1043466622001065"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2022.155897","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2022.155897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"155897"}}